Clinical Trial Update: Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14 [Phase 2]

View source ↗

Summary

Phase 2 trial update of axitinib in relapsed/refractory salivary gland cancers of the upper aerodigestive tract has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Salivary Gland Cancers | Phase 2 | Status: COMPLETED